CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Follow-Up Questions
What is CureVac NV (CVAC)'s P/E Ratio?
The P/E ratio of CureVac NV is 6.2859
What is the price performance of CVAC stock?
The current price of CVAC is 5.37, it has increased 0.38% in the last trading day.
What are the primary business themes or industries for CureVac NV?
CureVac NV belongs to Biotechnology industry and the sector is Health Care
What is CureVac NV market cap?
CureVac NV's current market cap is $1.2
Is CureVac NV a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for CureVac NV, including 2 strong buy, 4 buy, 7 hold, 0 sell, and 2 strong sell
